Abstract:Coronavirus disease 2019 (COVID19), caused by SARS-CoV-2, is a complex disease, with a variety of clinical manifestations ranging from asymptomatic infection or mild cold-like symptoms to more severe cases requiring hospitalization and critical care. The most severe presentations seem to be related with a delayed, deregulated immune response leading to exacerbated inflammation and organ damage with close similarities to sepsis. Methods: In order to improve the understanding on the relation between host immune response and disease course, we have studied the differences in the cellular (monocytes, CD8+ T and NK cells) and soluble (cytokines, chemokines and immunoregulatory ligands) immune response in blood between Healthy Donors (HD), COVID19 and a group of patients with non-COVID19 respiratory tract infections (NON-COV-RTI). In addition, the immune response profile has been analyzed in COVID19 patients according to disease severity. Results: In comparison to HDs and patients with NON-COV-RTI, COVID19 patients show a heterogeneous immune response with the presence of both activated and exhausted CD8+ T and NK cells characterised by the expression of the immune checkpoint LAG3 and the presence of the adaptive NK cell subset. An increased frequency of adaptive NK cells and a reduction of NK cells expressing the activating receptors NKp30 and NKp46 correlated with disease severity. Although both activated and exhausted NK cells expressing LAG3 were increased in moderate/severe cases, unsupervised cell clustering analyses revealed a more complex scenario with single NK cells expressing more than one immune checkpoint (PD1, TIM3 and/or LAG3). A general increased level of inflammatory cytokines and chemokines was found in COVID19 patients, some of which like IL18, IL1RA, IL36B and IL31, IL2, IFNα and TNFα, CXCL10, CCL2 and CCL8 were able to differentiate between COVID19 and NON-COV-RTI and correlated with bad prognosis (IL2, TNFα, IL1RA, CCL2, CXCL10 and CXCL9). Notably, we found that soluble NKG2D ligands from the MIC and ULBPs families were increased in COVID19 compared to NON-COV-RTI and correlated with disease severity. Conclusions: Our results provide a detailed comprehensive analysis of the presence of activated and exhausted CD8+T, NK and monocyte cell subsets as well as extracellular inflammatory factors beyond cytokines/chemokines, specifically associated to COVID19. Importantly, multivariate analysis including clinical, demographical and immunological experimental variables have allowed us to reveal specific immune signatures to i) differentiate COVID19 from other infections and ii) predict disease severity and the risk of death.

Immunoglobulins in COVID-19 pneumonia: from the acute phase to the recovery phase

Systems-Level Immunomonitoring from Acute to Recovery Phase of Severe COVID-19

COVID-19 neutralizing antibodies predict disease severity and survival

Antibody responses to common viruses according to COVID-19 severity and postacute sequelae of COVID-19

A Progressive Approach from Disease Onset until Outcome

COVID-19-neutralizing antibodies predict disease severity and survival

Immune Response and COVID-19: A mirror image of Sepsis

Immunologic mediators profile in COVID-19 convalescence

Impaired mucosal IgA response in patients with severe COVID-19

Humoral immune mechanisms involved in protective and pathological immunity during COVID-19

Integrated analysis of circulating immune cellular and soluble mediators reveals specific COVID19 signatures at hospital admission with utility for prediction of clinical outcomes

The kinetics of humoral response and its relationship with the disease severity in COVID-19

Characterization of the Inflammatory Response to Severe COVID-19 Illness

[COVID-19 from the Perspective of Haematology and Haemostaseology]

Serum Inflammatory Factors Are Positively Correlated with the Production of Specific Antibodies in Coronavirus Disease 2019 Patients

Impact of Immunoglobulin M-enriched Immunoglobulins on the Outcomes of Severe Coronavirus Disease 2019

Proinflammatory IgG Fc structures in patients with severe COVID-19

Immune reactivity during COVID-19: Implications for treatment

COVID-19: In the Eye of the Cytokine Storm

The Dynamic Changes of Antibodies Against SARS-CoV-2 During the Infection and Recovery of COVID-19

The Characterization of Disease Severity Associated IgG Subclasses Response in COVID-19 Patients